Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of PT010, a Single Dose of PT009, and a Single Dose of Open-Label Symbicort(R) Turbohaler(R) in Healthy Subjects

Next Previous
Trial Profile

A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of PT010, a Single Dose of PT009, and a Single Dose of Open-Label Symbicort(R) Turbohaler(R) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Budesonide/formoterol; Budesonide/formoterol
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Pearl Therapeutics

Most Recent Events

  • 21 Mar 2020 Results of pooled analysis of four studies (NCT01980615, NCT02189304, NCT03075267, NCT02197975) presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 05 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 28 Aug 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top